Cancer Communications

Papers
(The H4-Index of Cancer Communications is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
529
Issue Information501
Issue Information320
Kindlin‐1 drives early steps of breast cancer metastasis302
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”229
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma219
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation218
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma204
Issue Information194
180
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort178
173
Age‐specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross‐sectional study160
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity152
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy143
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study138
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update137
Current status and perspectives of esophageal cancer: a comprehensive review130
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives122
Research trends of cancer metabolism: analysis from a Chinese perspective121
Issue Information121
118
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases114
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial110
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study103
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h103
102
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses97
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer95
Issue Information89
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of 81
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer79
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica77
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions70
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence69
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer66
N 6 ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas64
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer63
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program61
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy59
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity57
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward57
Issue Information56
55
Cover Image, Volume 45, Issue 654
54
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials54
Cover Image, Volume 42, Issue 152
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma52
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism50
0.11659598350525